Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 125.85 |
| Open | 127.24 |
| Bid | 125.03 x 800 |
| Ask | 125.59 x 800 |
| Day's range | 125.05 - 128.70 |
| 52-week range | 99.14 - 134.63 |
| Volume | |
| Avg. volume | 8,233,711 |
| Market cap | 317.26B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 139.18 |
| EPS (TTM) | 0.90 |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | 3.08 (2.46%) |
| Ex-dividend date | 16 Sept 2024 |
| 1y target est | 143.28 |
Business WireMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
RAHWAY, N.J., July 26, 2024--Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Advanced Bladder Cancer
BenzingaMerck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
On Tuesday, Merck & Co Inc (NYSE:MRK) shared topline results from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab (MK-1654). Clesrovimab is the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease. Clesrovimab met its primary safety and efficacy endpoints in the trial, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150. Participants were randomized to
Business WireMerck Announces Fourth-Quarter 2024 Dividend
RAHWAY, N.J., July 23, 2024--Merck Announces Fourth-Quarter 2024 Dividend
© 2024 Yahoo. All rights reserved.